Drug Trial Radar · NCT05407246
Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis
Last checked: Nov 19, 2026Latest source record: Jan 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Aug 5, 2022
Primary completion
Aug 18, 2023
Study completion Aug 18, 2023
Sponsor
- Lead sponsor
- Tianjin Hemay Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study. The study was divided into three stages, including screening period(4-week), treatment period(16-week) and observation period. All subjects need to enter a 28 day (4-week) observation period after stopping hemay005 treatment. Main purpose: The efficacy of hemay005 tablet in the treatment of active ankylosing spondylitis (as) was evaluated by placebo parallel control. Secondary purpose: * To evaluate the safety of oral hemay005 tablets in patients with active as. * To evaluate the population pharmacokinetics of hemay005 tablets in patients with active as.
Conditions
- Active Ankylosing Spondylitis
Interventions
Hemay005Drug
Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;
Primary outcomes
What the sponsor says the trial is designed to measure.
- ASAS20Time frame: week 16
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical University
Hefei, Anhui, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
The Third Affiliated Hospital of Sun Yat sen University
Guangzhou, Guangdong, China
Hebei CNPC Central Hospital
Langfang, Hebei, China
Puyang Oilfield General Hospital
Puyang, Henan, China
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology
Wuhan, Hubei, China
Chenzhou first people's Hospital
Chenzhou, Hunan, China
Pingxiang people's Hospital
Pingxiang, Jiangxi, China
Jilin Provincial People's Hospital
Changchun, Jilin, China
The First Affiliated Hospital of Medical College of Xi'an Jiaotong University
Xi’an, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.